Citations

Clear

9383 citation(s) found for "Thomas, PS".

Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Risedronate for the Prevention of Bone Loss in Premenopausal Women Undergoing Chemotherapy for Primary Breast Cancer
Hines, Stephanie L., Mincey, Betty A., Sloan, Jeff A. , Thomas, Sachdev , Chottiner, Elaine G., Loprinzi, Charles L. , Carlson, Mark D., Atherton, Pamela J., Salim, Muhammad , Perez, Edith A. , Atherton, Philip J. , Atherton, Pamela J., Atherton, Philip J.

Mayo Clinic

Journal of Clinical Oncology | December 16, 2008 | Volume: 27 | Issue: 7 | Pages: 1047-1053

10.1200/jco.2008.19.1783 | PMID 19075260 Get It

Purpose Risedronate prevents bone loss in postmenopausal women. The purpose of this study was to determine whether risedronate prevents bone loss in premenopausal women undergoing chemotherapy for breast cancer. Patients and Methods Premenopausal women undergoing chemotherapy for breast cancer were treated with oral calcium 600 mg and vitamin D 400 U daily and randomly assigned to receive oral risedronate 35 mg weekly or placebo, with all these therapies beginning within a month of the start of chemotherapy. Most chemotherapy regimens included anthracyclines, taxanes, or cyclophosphamide. Bone mineral density (BMD) was measured at baseline and 1 year. The primary end point was the change in lumbar spine (LS) BMD from baseline to 1 year. Results A total of 216 women enrolled; 170 women provided BMD data at 1 year. There was no difference in the mean change or percent change in LS BMD between groups, with a loss of 4.3% in the risedronate arm and 5.4% for placebo at 1 year (P = .18). Loss of BMD at the femoral neck and total hip were also similar between treatment groups. Risedronate was well tolerated, with no significant differences in adverse events compared with placebo, except that arthralgias and chest pain were worse in those receiving the placebos. Conclusion Risedronate did not prevent bone loss in premenopausal women undergoing adjuvant chemotherapy for breast cancer.
The Prognostic Value of Cardiopulmonary Exercise Testing in Idiopathic Pulmonary Fibrosis
Fell, Charlene D. , Liu, Lyrica Xiaohong, Motika, Caroline, Kazerooni, Ella A. , Gross, Barry H., Colby, Thomas V. , Murray, Susan , Toews, Galen B., Flaherty, Kevin R. , Motika, Caroline A., Travis, William D. , Martínez, Fernando J.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | December 12, 2008 | Volume: 179 | Issue: 5 | Pages: 402-407

10.1164/rccm.200802-241oc | PMID 19074597 Get It

Abstract Rationale Idiopathic pulmonary fibrosis (IPF) is characterized by progressive dyspnea, impaired gas exchange, and ultimate mortality. Objectives To test the hypothesis that maximal oxygen uptake during cardiopulmonary exercise testing at baseline and with short-term longitudinal measures would predict mortality in patients with idiopathic pulmonary fibrosis. Methods Data from 117 patients with IPF and longitudinal cardiopulmonary exercise tests were examined retrospectively. Survival was calculated from the date of the first cardiopulmonary exercise test. Measurements and Main Results Patients with baseline maximal oxygen uptake less than 8.3 ml/kg/min had an increased risk of death (n = 8; hazard ratio, 3.24; 95% confidence interval, 1.10–9.56; P = 0.03) after adjusting for age, gender, smoking status, baseline forced vital capacity, and baseline diffusion capacity for carbon monoxide. We were unable to define a unit change in maximal oxygen uptake that predicted survival in our cohort. Conclusions We conclude that a threshold maximal oxygen uptake of 8.3 ml/kg/min during cardiopulmonary exercise testing at baseline adds prognostic information for patients with IPF.
The Association of Transient Ischemic Attack Symptoms With Memory Impairment Among Elderly Participants of the Third US National Health and Nutrition Examination Survey
Takahashi, Paul Y. , Thomas, Kris G., Cedeno, Onelis Quirindongo, North, Frederick , Stroebel, Robert J. , DeJesus, Ramona S. , Targonski, Paul V., Dyrbye, Liselotte N. , Takahashi, Paul

Mayo Clinic

Journal of Geriatric Psychiatry and Neurology | December 10, 2008 | Volume: 22 | Issue: 1 | Pages: 46-51

10.1177/0891988708328218 | PMID 19073836 Get It

Background and Purpose: Stroke is a well-known risk factor for vascular dementia. However, the association of transient ischemic attacks with cognitive impairment is less well-established. Methods: Records from Third National Health and Nutrition Examination Survey were abstracted for demographic and medical information for participants with an age !60 years who reported being free of stroke. Five self-reported symptoms (weakness, numbness, loss of vision, inability to speak, and severe dizziness) were used as surrogates representing transient ischemic attacks. Information on conventional risk factors for vascular dementia was also obtained. Multivariable logistic regression was used to examine risk factors for memory impairment. Results: 4617 participants were included with a sample-weighted prevalence of memory impairment of 6.6% (1417 participants). The final multivariable analysis revealed a significant association between transient weakness and memory impairment (odds ratio 1.52, 95% CI 1.11-2.07). The other 4 transient ischemic attacks symptoms were not significantly associated with memory impairment in the final model. Systolic blood pressure >140 was most strongly associated with prevalent memory impairment (odds ratio, 9.78, 95% CI 1.49-64.3). Other associated risk factors included non-white race, male gender, age, education ≤12 years, and history of any alcohol use. Conclusion: Among transient ischemic attacks symptoms, self-reported weakness in the face, arm, or leg was significantly associated with memory impairment. This study indicates that transient ischemic attacks symptoms are, even in the absence of stroke, associated with memory impairment. Aggressive risk factor modification in patients with TIA symptoms may be warranted to prevent potential future memory loss.
Phase I Versus Palliative Care: Striking the Right Balance
Schapira, Lidia , Moynihan, Timothy J. , Gunten, Charles F. von , Smith, Thomas J. , Smith, Thomas J

Mayo Clinic

Journal of Clinical Oncology | December 9, 2008 | Volume: 27 | Issue: 2 | Pages: 307-308

10.1200/jco.2008.20.7803 | PMID 19064948 Get It

Impact of Body Mass Index and Weight Change After Treatment on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From Cancer and Leukemia Group B 89803
Meyerhardt, Jeffrey A. , Niedzwiecki, Donna , Hollis, Donna, Saltz, Leonard B. , Nelson, Heidi , Whittom, Renaud , Hantel, Alexander, Fuchs, Charles S. , Mayer, Robert J. , Thomas, James , Saltz, Leonard , Meyerhardt, Jeffrey A , Niedzwiecki, Donna

Mayo Clinic

Journal of Clinical Oncology | November 26, 2008 | Volume: 26 | Issue: 25 | Pages: 4109-4115

10.1200/jco.2007.15.6687 | PMID 18757324 Get It

Purpose Obesity is a risk factor for the development of colon cancer. However, the influence of body mass index (BMI) on the outcome of patients with established colon cancer remains uncertain. Moreover, the impact of change in body habitus after diagnosis has not been studied. Patients and Methods We conducted a prospective, observational study of 1,053 patients who had stage III colon cancer and who were enrolled on a randomized trial of adjuvant chemotherapy. Patients reported on height and weight during and 6 months after adjuvant chemotherapy. Patients were observed for cancer recurrence or death. Results In this cohort of patients with stage III cancer, 35% of patients were overweight (BMI, 25 to 29.9 kg/m2), and 34% were obese (BMI ≥ 30 kg/m2). Increased BMI was not significantly associated with a higher risk of colon cancer recurrence or death (P trend = .54). Compared with normal-weight patients (BMI, 21 to 24.9 kg/m2), the multivariate hazard ratio for disease-free survival was 1.00 (95% CI, 0.72 to 1.40) for patients with class I obesity (BMI, 30 to 34.9 kg/m2) and 1.24 (95% CI, 0.84 to 1.83) for those with class II to III obesity (BMI ≥ 35 kg/m2) after analysis was adjusted for tumor-related prognostic factors, physical activity, tobacco history, performance status, age, and sex. Similarly, after analysis was controlled for BMI, weight change (either loss or gain) during the time period between ongoing adjuvant therapy and 6 months after completion of therapy did not significantly impact on cancer recurrence and/or mortality. Conclusion Neither BMI nor weight change was significantly associated with an increased risk of cancer recurrence and death in patients with colon cancer.
Sporadic Bilateral Optic Neuropathy in Children: The Role of Mitochondrial Abnormalities
Brodsky, Michael C., Abu‐Amero, Khaled K. , Bosley, Thomas M. , Glasier, Charles M.

Mayo Clinic

Investigative Opthalmology & Visual Science | November 26, 2008 | Volume: 49 | Issue: 12 | Pages: 5250

10.1167/iovs.08-2193 | PMID 18676632 Get It

Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab
Davis, Melanie E., Geyer, Susan M. , Leung, Nelson , Jelinek, Diane F., Tschumper, Renee C. , Secreto, Charla, Lin, Thomas S., Grever, Michael R. , Call, Timothy G. , Heerema, Nyla A. , Lozanski, Gerard , Byrd, John C. , Lucas, David , Byrd, John C. , Awan, Farrukh T. , Kay, Neil E. , Wu, Wenting , Shanafelt, Tait D. , Zent, Clive S. , Leung, Nelson , Byrd, John C

Mayo Clinic

Blood | November 13, 2008 | Volume: 113 | Issue: 3 | Pages: 535-537

10.1182/blood-2008-08-173450 | PMID 19008456 Get It

Abstract Myeloid cell leukemia-1 (Mcl-1) is an antiapoptotic member of the Bcl-2 protein family. Increased Mcl-1 expression is associated with failure to achieve remission after treatment with fludarabine and chlorambucil in patients with chronic lymphocytic leukemia (CLL). However, the influence of Mcl-1 expression has not been examined in CLL trials using chemoimmunotherapy. We investigated Mcl-1 protein expression prospectively as part of a phase 2 study evaluating the efficacy of pentostatin, cyclophosphamide, and rituximab in patients with untreated CLL. No significant difference by Mcl-1 expression was noted in pretreatment or response parameters. However, in patients with higher Mcl-1 expression, both minimal residual disease-negative status and progression-free survival was found to be significantly reduced (57% vs 19%, P = .01; 50.8 vs 18.7 months; P = .02; respectively). Mcl-1 expression may therefore be useful in predicting poor response to chemoimmunotherapy. These findings further support pursuing treatment strategies targeting this important antiapoptotic protein. (Because the trials described were conducted before the requirement to register them was implemented, they are not registered in a clinical trial database.)
POLYRADICULOPATHY DUE TO METHOTREXATE-INDUCED EBV-ASSOCIATED LYMPHOPROLIFERATIVE DISORDER
Kumar, N. Girish , Sandroni, Paola , Steensma, David P. , Luthra, H. S., Habermann, Thomas M. , Steensma, David P

Mayo Clinic

Neurology | November 10, 2008 | Volume: 71 | Issue: 20 | Pages: 1644-1645

10.1212/01.wnl.0000334757.16882.37 | PMID 19001256 Get It

Genetic Variation in Tumor Necrosis Factor and the Nuclear Factor-κB Canonical Pathway and Risk of Non-Hodgkin's Lymphoma
Cerhan, James R. , Liu‐Mares, Wen, Fredericksen, Zachary S., Novak, Anne J. , Cunningham, Julie M. , Liebow, Mark , Wang, Alice H., Call, Timothy G. , Ansell, Stephen M. , Kay, Neil E. , Doǧan, Ahmet , Habermann, Thomas M. , Slager, Susan L. , Cerhan, James R

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | November 6, 2008 | Volume: 17 | Issue: 11 | Pages: 3161-3169

10.1158/1055-9965.epi-08-0536 | PMID 18990758 Get It

Abstract Non-Hodgkin's lymphoma (NHL) is a cancer closely associated with immune function, and the tumor necrosis factor (TNF) G-308A promoter polymorphism, which influences immune function and regulation, was recently reported by the InterLymph Consortium to be associated with NHL risk. TNF signaling activates the nuclear factor-κB (NF-κB) canonical pathway, leading to transcriptional activation of multiple genes that influence inflammation and immune response. We hypothesized that, in addition to TNF signaling, common genetic variation in genes from the NF-κB canonical pathway may affect risk of NHL. We genotyped 54 single nucleotide polymorphisms (SNP) within TNF, lymphotoxin A LTA, and nine NF-κB genes from the canonical pathway (TNFRSF1A, TRADD, TRAF2, TRAF5, RIPK1, CHUK, IKBKB, NFKB1, and REL) in a clinic-based study of 441 incident cases and 475 frequency-matched controls. Tagging SNPs were selected from HapMap supplemented by putative functional SNPs for LTA/TNF. We used principal components and haplo.stats to model gene-level associations and logistic regression to model SNP-level associations. Compared with the wild-type (GG), the AA genotype for the TNF promoter polymorphism G-308A (rs1800629) was associated with increased risk of NHL [odds ratio (OR), 2.14; 95% confidence interval (95% CI), 0.94-4.85], whereas the GA genotype was not (OR, 1.00; 95% CI, 0.74-1.34). This association was similar for follicular lymphoma and diffuse large B-cell lymphoma. A previously reported LTA/TNF haplotype was also associated with NHL risk. In gene-level analysis of the NF-κB pathway, only NFKB1 showed a statistically significant association with NHL (P = 0.049), and one NFKB1 tagSNP (rs4648022) was associated with NHL risk overall (ordinal OR, 0.59; 95% CI, 0.41-0.84; Ptrend = 0.0037) and for each of the common subtypes. In conclusion, we provide additional evidence for the role of genetic variation in TNF and LTA SNPs and haplotypes with risk of NHL and also provide some of the first preliminary evidence for an association of genetic variation in NFKB1, a downstream target of TNF signaling, with risk of NHL. (Cancer Epidemiol Biomarkers Prev 2008;17(11):3161–9)
An Automated Approach for Estimation of Breast Density
Heine, John , Carston, Michael J., Scott, Christopher G. , Brandt, Kathleen R. , Wu, Fang-Fang, Sellers, Thomas A. , Vachon, Celine M. , Pankratz, V. Shane , Vachon, Celine M. , Scott, Christopher

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | November 6, 2008 | Volume: 17 | Issue: 11 | Pages: 3090-3097

10.1158/1055-9965.epi-08-0170 | PMID 18990749 Get It

Abstract Breast density is a strong risk factor for breast cancer; however, no standard assessment method exists. An automated breast density method was modified and compared with a semi-automated, user-assisted thresholding method (Cumulus method) and the Breast Imaging Reporting and Data System four-category tissue composition measure for their ability to predict future breast cancer risk. The three estimation methods were evaluated in a matched breast cancer case-control (n = 372 and n = 713, respectively) study at the Mayo Clinic using digitized film mammograms. Mammograms from the craniocaudal view of the noncancerous breast were acquired on average 7 years before diagnosis. Two controls with no previous history of breast cancer from the screening practice were matched to each case on age, number of previous screening mammograms, final screening exam date, menopausal status at this date, interval between earliest and latest available mammograms, and residence. Both Pearson linear correlation (R) and Spearman rank correlation (r) coefficients were used for comparing the three methods as appropriate. Conditional logistic regression was used to estimate the risk for breast cancer (odds ratios and 95% confidence intervals) associated with the quartiles of percent breast density (automated breast density method, Cumulus method) or Breast Imaging Reporting and Data System categories. The area under the receiver operator characteristic curve was estimated and used to compare the discriminatory capabilities of each approach. The continuous measures (automated breast density method and Cumulus method) were highly correlated with each other (R = 0.70) but less with Breast Imaging Reporting and Data System (r = 0.49 for automated breast density method and r = 0.57 for Cumulus method). Risk estimates associated with the lowest to highest quartiles of automated breast density method were greater in magnitude [odds ratios: 1.0 (reference), 2.3, 3.0, 5.2; P trend < 0.001] than the corresponding quartiles for the Cumulus method [odds ratios: 1.0 (reference), 1.7, 2.1, and 3.8; P trend < 0.001] and Breast Imaging Reporting and Data System [odds ratios: 1.0 (reference), 1.6, 1.5, 2.6; P trend < 0.001] method. However, all methods similarly discriminated between case and control status; areas under the receiver operator characteristic curve were 0.64, 0.63, and 0.61 for automated breast density method, Cumulus method, and Breast Imaging Reporting and Data System, respectively. The automated breast density method is a viable option for quantitatively assessing breast density from digitized film mammograms. (Cancer Epidemiol Biomarkers Prev 2008;17(11):3090–7)